Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Thyroid Neoplasms 8Head and Neck Neoplasms 8Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Thyroid Cancer, Papillary 6Lung Neoplasms 6Sarcoma 5Colorectal Neoplasms 5Colonic Neoplasms 5Breast Neoplasms 5Thyroid Diseases 4Thoracic Neoplasms 4Salivary Gland Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neuroendocrine Tumors 4Neoplasms by Site 4Melanoma 4Lung Diseases 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Nasopharyngeal Carcinoma 3Glioma 3Endometrial Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Medullary 3

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Squamous Cell Carcinoma of Head and Neck × Head & Neck × Clear all
NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
401 enrolled 1 FDA
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡